Tech Company Financing Transactions
Esperance Pharmaceuticals Funding Round
Sanofi-Genzyme BioVentures, Advantage Capital Partners and Louisiana Fund joined a $7.5 million Series B funding round for Esperance Pharmaceuticals. The round was announced on 6/1/2011.
Transaction Overview
Company Name
Announced On
6/1/2011
Transaction Type
Venture Equity
Amount
$7,500,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the Series B will support further clinical development of EP-100, the lead cancer-targeting drug candidate from Esperance's Cationic Lytic Peptide (CLYP�) platform technology and the continued expansion of the Company's pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
909 Fannin St. 2000
Houston, TX 77010
USA
Houston, TX 77010
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Esperance Pharmaceuticalsdevelops anticancer drugsthat kill cancer cells without harming normal cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hector Alila
Chief Financial Officer
Clarice Motter
VP - R & D
Carola Leuschner
Browse more venture capital transactions:
Prev: 6/1/2011: Alliance Health venture capital transaction
Next: 6/1/2011: Act-On Software venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs